Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Incidence and Severity of Retinopathy of Prematurity (ROP) is Reduced in Extremely Low Gestational Age (GA) Newborns (ELGANS) Treated with Recombinant Human Cu/Zn Superoxide Dismutase (rhSOD)

Incidence and Severity of Retinopathy of Prematurity (ROP) is Reduced in Extremely Low Gestational Age (GA) Newborns (ELGANS) Treated with Recombinant Human Cu/Zn Superoxide Dismutase (rhSOD). Pediatric Research. 2007; E-PAS2007:618225.6.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.